Safety and Efficacy of NB-001 in 22q11DS Children with Anxiety, Inattention, and/or Autism

Safety and Efficacy of NB-001 in 22q11DS Children with Anxiety, Inattention, and/or Autism

Contact

 If you are interested in participating in the study or want to learn more, please get in touch. Contact us
This study is no longer recruiting.

Description
The aim of this study is to determine if NB-001 (an investigational drug that is not approved by the FDA) is effective, safe, and well tolerated in treating children and adolescents with 22q11DS and anxiety, inattention, and/or autism. The study will take place over a 21-week period with routine telemedicine check-ins, home health nurse visits, and behavioral questionnaires. Except for the first visit which will be in-person at the CHOP Philadelphia campus, all other study visits will be done at the patient's home by a study nurse.  

Eligibility and criteria
IRB Number:
21-018574
Eligible age range:
6 years - 17 years
Clinical trial phase:
Phase II
Official title:
Safety and Efficacy of NB-001 in Children with 22q11.2 Deletion Syndrome and Associated ADHD- Anxiety, and Autism Spectrum Disorder

What to expect

Visits will involve:

  • Physical examinations, Bloodwork (screening visit will require fasting and optional genetic testing), ECG, Urine tests
  • Telemedicine call with the study doctor
  • Behavioral questionnaires and interviews with a psychologist

Related specialties
Smiling CHOP patient holding shopping bag

We need families like you

Your time and participation make a difference in supporting the work of the Research Institute and children in our community. Learn more about opportunities to participate in our research.